ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Nome da criptoABBVON

ClassificaçãoNo.3140

Capitalização de mercado$0.00

Capitalização de mercado totalmente diluída$0.00

Market share%

Vol. de negociação/Capitalização de mercado (24h)451,599.18%

Fornecimento circulante210.07193405

Fornecimento máximo0

Fornecimento total210.07193405

Taxa circulante%

Data de emissão--

O preço quando o ativo foi emitido pela primeira vez--

Máximo histórico236.1976329606931,2026-03-03

Menor preço207.47261007076094,2026-02-04

Blockchain públicaETH

ApresentaçãoAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Setor

Midias sociais

• Site oficial
• Explorador de blocos

etfindex:mc_etfindex_sourceIsenção de responsabilidade: Os dados fornecidos por cmc e não devem ser considerados como conselhos de investimento.